SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

JNJ-632

Item No. 26325



CAS Registry No.:	1572510-42-9
Formal Name:	N-(4-fluoro-3-methylphenyl)-3-[[[(3S)-tetrahydro-3-furanyl]amino]sulfonyl]-benzamide
MF:	$C_{18}H_{19}FN_2O_4S$
FW:	378.4
Purity:	≥98%
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	≥2 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

JNJ-632 is supplied as a crystalline solid. A stock solution may be made by dissolving the JNJ-632 in the solvent of choice. JNJ-632 is soluble in the organic solvent DMSO, which should be purged with an inert gas, at a concentration of approximately 50 mg/ml.

Description

JNJ-632 is a modulator of hepatitis B virus (HBV) capsid assembly.[1,2] It reduces viral DNA load in HBV-infected HepG2.2.15 cells (EC_{50} = 121 nM) without affecting cell growth.[2] It also reduces viral DNA load in primary human hepatocytes infected with the HBV genotypes Ae, Bj, C, and D (EC_{50}s = 101, 240, 119, and 200 nM, respectively). JNJ-632 prevents formation of covalently closed circular DNA in HBV-infected primary human hepatocytes in a concentration-dependent manner when administered in combination with the HBV viral inoculum. *In vivo*, JNJ-632 (200 mg/kg per day) reduces plasma HBV DNA content in HBV-infected humanized mice.[1]

References

1. Vandyck, K., Rombouts, G., Stoops, B., *et al.* Synthesis and evaluation of N-phenyl-3-sulfamoyl-benzamide derivatives as capsid assembly modulators inhibiting hepatitis B virus (HBV). *J. Med. Chem.* **61(14)**, 6247-6260 (2018).
2. Berke, J.M., Dehertogh, P., Vergauwen, K., *et al.* Capsid assembly modulators have a dual mechanism of action in primary human hepatocytes infected with hepatitis B virus. *Antimicrob. Agents Chemother.* **61(8)**, pii: e00560-176 (2017).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM